Press Releases Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 12:20:00 2026-03-13 pm EDT			5-day change	1st Jan Change
247.05 ^DKK	+0.02%		-0.34%	-24.04%

Mar. 14	How are different indices influenced?
Mar. 13	Form Health Joins Lilly Employer Connect Platform	CI

Press Releases

Mar. 12	WHO Foundation and Novo Nordisk Expand Collaboration to Provide Financial Support towards Strengthening Health Systems for Cardio-Renal-Metabolic Diseases	AQ
Mar. 10	Hims & Hers shares rise 50 per cent after Novo Nordisk withdraws lawsuit	AQ
Mar. 09	Hims & Hers Health and Novo Nordisk end lawsuit over weight loss medications, enter collaboration	AQ
Mar. 09	Hims & Hers agrees to stop selling compound versions of Novo Nordisk's Wegovy and other weight-loss drugs, ending suit	AQ
Mar. 09	Novo Nordisk A/S - share repurchase programme	GL
Mar. 02	Novo Nordisk invests 432 million euros in expanding Wegovy production in Ireland	AQ
Mar. 02	Election of employee representatives to the Board of Directors of Novo Nordisk A/S	GL
Mar. 02	Novo Nordisk A/S - share repurchase programme	GL
Mar. 02	Novo Nordisk announces more than 400 million euro expansion in its manufacturing facility in Athlone, Ireland	GL
Feb. 25	Novo Nordisk and Vivtex partner to develop next-generation oral medicines for obesity and diabetes	GL
Feb. 24	Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China	GL
Feb. 23	Novo Nordisk A/S - share repurchase programme	GL
Feb. 23	Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved	GL
Feb. 23	Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved	AQ
Feb. 20	Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S	GL
Feb. 19	NHS must keep medicine clawback down or lose investment, says Novo Nordisk boss	AQ
Feb. 17	Novo Nordisk A/S: The European Commission approves more effective dose of injectable Wegovy® for adults with obesity; clinical study showed people lost about 21% of their body weight on average	GL
Feb. 17	Camurus appoints Jane Buus Laursen as Chief Corporate Development Officer	AQ
Feb. 16	Novo Nordisk A/S - share repurchase programme	GL
Feb. 16	FDA Tightens The Belt On GLP-1 Compounding, Escalating Threat Of Enforcement	AQ
Feb. 13	Oral Semaglutide And The GLP-1 Compounding Reckoning: From Regulatory Ambiguity To FDA Enforcement, DOJ Referrals, And Novo Nordisk's Case Against Hims & Hers	AQ
Feb. 12	CEO of Novo Nordisk sees growth potential as Medicare starts reimbursing obesity drugs	AQ
Feb. 11	Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons	GL
Feb. 11	Karolinska Institutet: Molecular patterns behind unstable atherosclerosis identified	AQ
Feb. 10	Patents, Innovation & Where The Law Draws The Line	AQ